GLP-1 weight-loss drugs may pivot to treat Alzheimer’s.

Interesting research from the University of Toronto, which has a strong legacy and brand in this field. In ironic and stark contrast to the critical take linked above. “In yet another surprise attribute of the new class of obesity drugs, scientists have found that GLP-1 receptor agonists can also subdue brain inflammation, giving them a potential ‘superpower’ in the fight against Alzheimer’s and Parkinson’s diseases.” ~ learn more